Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13812295 | 0.84 | ALDH1A1 (0.39) | CA1CA2ALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL13773158 | 0.77 | MMP1 (0.36) | CA1CA2ALDH1A1NPSR1CA9 | |
| SCHEMBL85557 | 0.76 | NPSR1 (0.35) | ALDH1A1NPSR1SMN1; SMN2LMNAHTT | |
| SCHEMBL24443113 | 0.74 | CA1 (0.34) | CA1CA2 | |
| SCHEMBL19627366 | 0.73 | CA1 (0.41) | CA1CA2ALDH1A1CA9CA12 | |
| SCHEMBL28420215 | 0.72 | ALDH1A1 (0.44) | CA1CA2ALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL4070679 | 0.72 | NPSR1 (0.48) | CA1CA2ALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL14615842 | 0.72 | CA2 (0.50) | CA1CA2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL26607884 | 0.72 | CA1 (0.50) | CA1CA2ALDH1A1HPGDHTT | |
| SCHEMBL13764329 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287029-A1 | SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | CHENGDU SHIBEIKANG BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-4410786-A1 | SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230278991-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230278991-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-07 | — | — | US | disclosed |
| WO-2023046150-A1 | SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都施贝康生物医药科技有限公司 | 2023-03-30 | — | — | WO | disclosed |
| EP-3762393-B1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-113773300-B | Sulfonamide compound, preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-20210179594-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2021-06-17 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20150152097-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150072978-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8940737-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8889675-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | CA1 1370/4885CA2 3086/4885ALDH1A1 4176/4885 |
| US-20150072978-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | CA1 1452/4885CA2 3184/4885ALDH1A1 4319/4885 |
| US-20240287029-A1 | SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | P2RX3, P2RX5, P2RX2 | CA1 466/4885CA2 109/4885ALDH1A1 2252/4885 |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CA1 2494/4885CA2 3763/4885ALDH1A1 125/4885 |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2A1, BCL2L1, BCL2L11 | CA1 2045/4885CA2 3710/4885ALDH1A1 4415/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | CA1 4845/4885CA2 4391/4885ALDH1A1 554/4885 |
| US-20230278991-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | CA1 4844/4885CA2 4441/4885ALDH1A1 626/4885 |
| US-20150152097-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | CA1 1452/4885CA2 3184/4885ALDH1A1 4319/4885 |
| US-20210179594-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | CA1 4844/4885CA2 4441/4885ALDH1A1 626/4885 |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | CA1 3907/4885CA2 3915/4885ALDH1A1 200/4885 |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | BAX, BCL2, BCL3 | CA1 1452/4885CA2 3184/4885ALDH1A1 4319/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CA1 2504/4885CA2 3687/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.